OLIVEDA
OLIVE TREE PHARMACY

OLIVEDA INTERNATIONAL. INC.

# OLIVEDA INTERNATIONAL, INC.

# QUARTER END REPORT
# FOR THE PERIOD ENDED
# MARCH 31, 2017

# FINANCIAL STATEMENTS

# OLIVEDA

OLIVE TREE PHARMACY

OLIVEDA INTERNATIONAL. INC.

Oliveda International, Inc.
(OLIVEDA )
2425 Olympic Blvd Suite 145
Santa Monica, CA 90404

OLIVEDA UNAUDITED BALANCE SHEET &
FINANCIAL STATEMENTS

Issuer's most recent Pro Forma Balance Sheet & Financial Statements
for the period ended March 31, 2017

TABLE OF CONTENTS

**Oliveda International , Inc.**
**Pro Forma Balance Sheets**
**(Unaudited subject to change)**

| | | |
|---|---|---|
| | | March 31, 2017 |
| ASSETS | | |
| Current assets | | |
| Cash in bank | $ | 153,385 |
| Accounts receivable | | 738,718 |
| Total Current assets | | 892,102 |
| | | |
| Other assets | | |
| Long Term Investments | | 612,101 |
| Software | | 6,705 |
| Total other assets | | 618,806 |
| | | |
| Total Assets | $ | 1,510,909 |
| | | |
| LIABILITIES & STOCKHOLDERS' DEFICIT | | |
| | | |
| Current liabilities | | |
| Accounts payable | $ | 897,495 |
| Advances payable | | - |
| Note payable - related party | | - |
| Notes payable | | 22,422 |
| Total current liabilities | | 919,917 |
| | | |
| Stockholders' Deficit | | |
| Preferred stock, 25,000,000 shares authorized with $0.0001 par value. | | 30 |
| Common stock, 450,000,000 shares with $0.001 par value. | | 100,306 |
| | | |
| Paid in capital | | - |
| Consolidated Accounting | | (736,211) |
| Retained Earnings | | 635,875 |
| Net Income | | 590,991 |
| Total Stockholders' Deficit | | 590,991 |
| | | |
| Total Liabilities and Stockholders' Deficit | $ | 1,510,909 |

The accompanying notes are an integral part of these financial statements .

**Oliveda International , Inc.**
**Pro Forma Statements of Operations**
**(Unaudited subject to change)**

| | | Period Ended March 31, 2017 |
|---|---|---|
| REVENUE | | |
| Income | $ | 1,524,351 |
| Cost of revenues | | 316,628 |
| GROSS PROFIT | | 1,207,723 |
| | | |
| Operating Expenses: | | |
| Personnel Costs | | 155,426 |
| Write Downs | | - |
| Office Expenses | | 84,872 |
| Vehicle | | 9,750 |
| Advertising | | 141,437 |
| Rent | | 62,134 |
| Remaining Expenses | | - |
| Office Supplies | | 3,534 |
| Professional | | 153,096 |
| Telephone | | 2,079 |
| Travel | | 4,403 |
| Utilities | | - |
| General and administrative | | - |
| Total operating expenses | | 616,731 |
| | | |
| Income (loss) from operations | $ | 590,991 |
| | | |
| Other income (expense) | | |
| Interest expense | | - |
| Other income (expense) net | | - |
| | | |
| Net income (loss) | $ | 590,991 |
| | | |
| Net income (loss) per share (Basic and fully diluted) | $ | 0.0058 |
| | | |
| Weighted average number of common shares outstanding | | 101,305,870 |

The accompanying notes are an integral part of these financial statements

**Oliveda International , Inc.**
**Pro Forma Condensed Statement of Cash Flows**
**(Unaudited subject to change)**

| | | For Period ended March 31, |
|---|---|---|
| | | **2017** |
| **Cash Flows From Operating Activities** | | |
| Net Income ( Loss) | $ | 590,991 |
| | | |
| Amortization and Impairment | | - |
| Depreciation | | (17,538) |
| **Activities** | $ | 573,454 |
| | | |
| Accounts Payable | | 897,495 |
| Accounts Receivable | | (738,718) |
| Accruded Interest | | - |
| Other Accrued Expenses | | - |
| **Changes in Operating Assets and Liabilities** | $ | 158,777 |
| | | |
| **Net Cash Used by Operating Activities** | $ | 732,231 |
| Notes Payable | | |
| Preferred Stock | | - |
| Common Stock | | - |
| Paid in Capital | | - |
| Retined Earnings | | - |
| **Cash Flows from Financing Activities** | | - |
| | | |
| **Net Increase /( Decrease) in Cash** | | 88,317 |
| Cash Beginning of Period | | 836,698 |
| **Cash, End of Period** | $ | 925,015 |

The accompanying notes are an integral part of these condensed financial statements

**Oliveda International , Inc.**
**Condensed Consolidated Statement of Changes in Stockholders ' Deficit**
**(Unaudited subject to change)**

| | Common Stock Shares | Amount ($0.001 Par) | Paid in Capital | Consolidation Accounting | Accumulated Equity (Deficit) | Stockholders' Equity (Deficit) |
|---|---|---|---|---|---|---|
| Balances - December 31, 2015 | 100,335,870 | $ 100,336 | $ 13,915 | $ (560,789) | $ 446,538 | $ 956,745 |
| | | $ - | | $ - | | |
| Consolidated Accounting | | | $ (13,915) | $ (175,422) | $ 189,337 | $ 13,915 |
| Balances - December 31, 2016 | 100,335,870 | $ 100,336 | $ - | $ (736,211) | $ 635,875 | $ 970,660 |

The accompanying notes are an integrgal part of these financial statements.

OLIVEDA
OLIVE TREE PHARMACY

OLIVEDA INTERNATIONAL. INC.

# NOTES TO FINANCIAL STATEMENTS

## March 31, 2017

## NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

### Organization and History

Oliveda International, Inc. (the "Company" or "Oliveda ") was incorporated in the State of Nevada on February 9, 2005. On March 31, 2017, Company, acquired an ownership interest in Oliveda International, Inc., a Colorado Corporation, a corporation that was closely held and owns Oliveda Deutschland GmbH.

The Company is a Nevada corporation organized for the purpose of engaging in any lawful business. The Company's acquisition of Oliveda International, Inc. allowed it to develop its basis of business operations that focuses on movie production, distribution and promotion and any other related business activities as of the date of these financial statements. It currently trades on the Pink Sheet under the symbol "OLVI". The Company's fiscal year end is December 31st.

The financial statements include the Company and its wholly owned subsidiaries; all significant inter- company balances and transactions are eliminated.

### Mergers And Acquisitions

On March 31, 2017, Oliveda International, Inc of Colorado was acquired.

### Management, Operations and Risk

Oliveda International has operations worldwide via its wholly owned subsidiary Oliveda Deutschland GmbH. With over 20 years of manufacturing and distribution of cosmetic and holistic products built around the pure essence of hte olive tree and oil oils. The company has a complete line of products that includes face, body hair and products for inside the body holistic benefits. The lines are extensive with facial washes, serums, eye care products, and facial oils, for the face. The body line of products includes washes, body oils hand and foot care products along with other bathing products. The holistic products include products based upon the wholesome essence of extra virgin olive oil, with mouth drawing oils, Orac and Camu Camu concentrate, Hydroxyyrosol Molecule, Tea Olivematcha, and other products that have been show to help the body perform more efficiently. The hari products include both shampoo and conditioners that are foremost in the industry.

The company has been successful selling the products through various channels, with both traditional distribution channels and through its own corporately owned stores. The company intends to open more of its owns stores worldwide in the coming years, with a target of 60 stores in 5 years worldwide. With its current stronghold in Europe, the company intends to reach out into the US, and Asian markets in the next 12 months.

The primary focus of Oliveda during fiscal year 2016 was to restructure the Company's balance sheet and capital structure while continuing the acquisition and development of the divisions described above.

On February 28, 2017 The board convened and voted to approve the changes proposed by Thomas Lommel, which included the share restructure and acquisition of Oliveda International, Inc.

All of the aforementioned activities involve complex business and financial transactions and there can be no guarantee that the Company will be able to successfully develop its business plan nor complete any or all of the transactions necessary for successful growth.

Volatile market conditions and the ongoing uncertainty of the global economic outlook could stymie any potential growth the Company plans on achieving at any time and increase the pressure on an already strained corporate financial structure. In order to continue the development of its two divisions, the Company must be successful in acquiring the necessary funding it is seeking. The inability to do so will result in the Company experiencing serious delays in implementing its business plan. Any or all of the above uncertainties could have a material adverse effect on the Company. Critical to success will be the ability to attract a strong management team at both the parent company and the divisional levels. As acquisition and financial transactions, even at a basic level, become more complex, the financial and managerial experience of the Company's management team will play a major role in the success or failure of the Company.

**Authorized Common Stock**

As of March 31, 2017, Oliveda had an authorized common stock capital of 500,000,000 shares with a par value of $.0001. Authorized preferred stands at 25,000,000 shares with a par value of $.00001. These numbers remain unchanged as of the date of this filing and the Company has no current plans for any increase thereof.

**Issued and Outstanding Common Stock**

As of March 31, 2017, Oliveda had a total of 101,305,870 Common Shares issued and outstanding.

On March 31, 2017, the Company issued 100,000,000 Common Shares in exchange for assets acquired from Oliveda International, Inc. a company controlled by Thomas Lommel.

No other Common Shares were issued during the fiscal 2016.

The Company has not entered into any agreement to promote its stock nor has it authorized any third party to conduct any type of promotion on its behalf.

**Authorized and Issued and Outstanding Preferred Stock**

As of March 31, 2017, Oliveda has authorized 25,000,000 Preferred shares, with 1,000,0000 designated as Class A Preferred Shares and 1,000,000 outstanding and 11,000,000 designated as Class B Preferred Shares of which 2,000,000 are outstanding,

**Transfer Agent**

During the period ended March 31, 2017, the Company's transfer agent, Interwest Stock Transfer, and the Company have reconciled the transfer agent records with the records of the Company and those of the State of Nevada.

**Additional Organizational Items**

None

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Cash and cash equivalents**

The Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties and all highly liquid investments with an original maturity of three months or less as cash equivalents.

**Revenue recognition**

The Company has realized minimal revenues from operations. The Company recognizes revenues when the sale and/or distribution of products is complete, risk of loss and title to the products have transferred to the customer, there is persuasive evidence of an agreement, acceptance has been approved by the customer, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable. Net sales will be comprised of gross revenues less expected returns, trade accounts, and customer allowances that will include costs associated with off-invoice markdowns and other price reductions, as well as trade promotions and coupons. The incentive costs will be recognized at the later of the date on which the Company recognized the related revenue or the date on which the Company offers the incentive.

**Basic and Diluted Loss per Share**

The Company computes loss per share in accordance with "ASC-260," "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common share during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive.

**Income Taxes**

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.

The Company maintains a valuation allowance with respect to deferred tax asset. Greenhouse Solutions establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company's financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carry-forward period under Federal tax laws.

Changes in circumstances, such as the Company generating taxable income, could cause a change in judgment about the reliability of the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change estimate.

**Carrying Value, Recoverability and Impairment of Long-Lived Assets**

The Company has adopted paragraph 360-10-35-17 of FASB Accounting Standards Codification for its long-lived assets. The Company's long –lived assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable.

The company assesses the recoverability of its long-lived assets by comparing the projected unaccounted net cash flows associated with the related long-lived asset or group of assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the assets expected future accounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.

The Company considers the following to be some examples of important indicators that may trigger an impairment review; (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company's overall strategy with respect to the manner of use of the acquired assets or changes in the Company's overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company's stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates acquired assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events.

The impairment charges, if any, are included in operating expenses in the accompanying statements of operations.

**Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

The Company’s significant estimates include income taxes provision and valuation allowance of deferred tax assets; the fair value of financial instruments; the carrying value and recoverability of long-lived assets, and the assumption that the Company will continue as a going concern. Those significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to those estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.

Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

**Fair value of Financial Instruments**

The estimated fair values of financial instruments were determined by management using available market information and appropriate valuation methodologies. The carrying amounts of financial instruments including cash approximate their fair value because of their short maturities.

**Long Lived Assets**

In accordance with ASC 350 the Company regularly reviews the carrying value of intangible and other long lived assets for the existence of facts or circumstances both internally and externally that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long lived asset exceeds its fair value.

**Stock-based Compensation**

The Company accounts for stock-based compensation issued to employees based on FASB accounting standard for Share Based Payment. It requires an entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award – the requisite service period (usually the vesting period). It requires that the compensation cost relating to share-based payment transactions be recognized in financial statements. That cost will be measured based on the fair value of the equity or liability instruments issued. The scope of the FASB accounting standard includes a wide range of share-based compensation arrangements including share options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans.

**Recent pronouncements**

Management has evaluated accounting standards and interpretations issued but not yet effective as of March 31, 2017, and does not expect such pronouncements to have a material impact on the Company’s financial position, operations, or cash flows.

**NOTE 3 – STOCKHOLDER'S DEFICIT**

The total number of common shares authorized that may be issued by the Company is 500,000,000 shares with a par value of $0.001 per share. The Company is authorized to issue 25,000,000 shares of preferred stock with a par value of $0.001 per share. As at March 31, 2017 there are 3,000,000 preferred shares issued and outstanding.

As at March 31, 2017 the total number of common shares outstanding was 101,305,870. The Company has an ongoing program of private placements to raise funds to support the operations. During the period ended March 31, 2017 the Company entered into an acquisition agreement with Oliveda International, Inc. of Colorado whereby the sole shareholder would surrender their stock and Oliveda would acquire a 100% working interest in the Company.

**NOTE 4 – GOING CONCERN**

Even though these financial statements are not audited it is management's opinion that an auditor would express a "going concern" statement.

**NOTE 5 - SUBSEQUENT EVENTS**

The Company has investigated and determined that there are no substantive events that have occurred since the end of this reporting period and the date of the filing of theses financial statements.